Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$8.88
▲ $0.02 (+0.3%)
Market data updated: 09/21 03:03 PM
News analyzed: 09/21/2026
Market Cap
$511.96M
Day Range
$8.84 - $8.96
52-Week Range
$6.50 - $9.35
Beta
—
Next Earnings
09.11.2026
Support
$6.85
Resistance
$8.88
KMDA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+27.2% (1Y)
🟡 Moderate
Strengths: 10/13 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 50
Price is above the 50-day average
Technical
Biggest negative driver
Stochastic
%K 96.9 — overbought
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Kamada (KMDA) holds an Investor Score of 85 and a STRONG rating, driven primarily by robust technical indicators and favorable news sentiment. Technically, the stock trades above its 50- and 200-day moving averages, signaling a bullish trend, while a positive MACD histogram and an RSI of 65.4 reflect healthy upward momentum. However, the stochastic %K reading of 96.9 points to an overbought condition that could precede a short‑term pullback. The news landscape further bolsters the score, with multiple reports highlighting Kamada's sufficient KedRAB supply amid rising U.S. rabies exposures, suggesting strong demand fundamentals. While most news items are positive or neutral, a note about the company's presentation at the H.C. Wainwright conference introduces a minor negative angle, potentially adding short‑term volatility. Risk metrics reveal a moderate risk profile: an ATR of 3% of price indicates modest price fluctuation, and a Calmar ratio of 0.61 (18.9% annualized return versus a 30.9% max drawdown) suggests limited risk‑adjusted performance. The combination of strong momentum, supportive demand news, and a middling risk score results in an overall high investor score, tempered by the overbought signal and the inherent volatility reflected in the risk metrics.
Price sits above both the 50‑day and 200‑day moving averages, MACD histogram is positive, RSI is 65.4, but stochastic %K is 96.9 indicating overbought conditions.
These metrics together show strong current momentum with a warning of possible near‑term reversal.
Recent news emphasizes Kamada's sufficient KedRAB supply amid rising U.S. rabies exposures, creating a positive demand narrative, with only a neutral/negative mention of an upcoming investor conference.
Positive supply and demand coverage supports confidence, while conference mentions may cause short‑term price swings.
ATR equals 3% of the price and the Calmar ratio is 0.61, reflecting moderate volatility and a modest risk‑adjusted return.
These figures indicate the stock can experience noticeable drawdowns relative to its return potential.
StockIQ conclusion
Kamada demonstrates solid technical strength and favorable news fundamentals, contributing to a high investor score. While the overbought stochastic reading and moderate risk metrics introduce caution, the overall profile suggests resilience, pending any major supply, regulatory, or market shifts.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
as of 09/10/202685
This Week
75
7D Ago
↑ +10
Improving
Technical
89
7D Ago: 81
↑ +8
News
92
7D Ago: 74
↑ +18
Risk
50
7D Ago: 50
→ 0
Biggest Improvements
📊 Score History
85
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $8.85
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
today · $8.85
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
1d ago · $8.85
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
1d ago · $8.85
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
1d ago · $8.85
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
1d ago · $8.85
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
2d ago · $8.85
Evidence: FOMO score jumped from 15 to 44 day-over-day
What happened after
Still awaiting outcome
2d ago · $8.85
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
Still awaiting outcome
2d ago · $8.85
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
85 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 27, 2026
Then
79
$8.38
Now
85
$8.88
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
89
Risk
50
Sentiment
92
Fundamental
No data available
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Kamada Ltd.** has centered on its financial performance and shareholder updates. The company declared a **$0.17 cash dividend per share** in August 2026, alongside record revenue and profitability for Q2 2026, while addressing **withholding tax procedures** for the dividend. Analysts highlighted its strong growth potential, projecting a **79% stock surge** and praising its **38% EPS growth**. Additionally, a director exercised stock options worth **$77K**, and Kamada was included in discussions about resilient healthcare stocks amid AI market shifts.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Kamada Ltd.. News trend score: 92. Reason: 9 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
40
🎯 Conviction (vs. Emotion)
50
Psychology
93
Fundamentals
—
Technical
89
Valuation
—
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+21%
Market Narrative
68
Fundamental Reality
50
Narrative Gap
+18
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
KMDA’s psychology is fragmented, with **herding** (23) and **FOMO** (22) competing for dominance. The stock’s underperformance relative to peers today suggests traders are aligning with broader sector moves, while momentum and sentiment keep FOMO alive. The narrative gap (8-point divergence) hints at potential misalignment between market expectations and fundamentals. Key question: Will herding persist if peers stabilize, or will FOMO drive further participation? Anchoring near resistance may cap upside unless sentiment shifts decisively.
Updated: 09/09/2026, 01:27 PM
What could change this?
👥 What the crowd believes
"The Company Reported Record-High Revenue and Profitability for First Six Months of 2026"
"Kamada Declares Cash Dividend of $0.17 Per Share"
"Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%"
🧠 Market Brain events driving this
📈 16D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Jesse Livermore — 64/100
🔴 Weakest match
Samuel Armstrong Nelson — 5/100
🗣️ Why do they disagree?
Based on Charles Mackay's documented crowd‑excitement principles, the model estimates a relatively positive tilt (score 63) indicating emerging enthusiasm for KMDA. By contrast, the fundamental‑value lenses of Smith, Graham, Fisher, Lynch, Bagehot and Veblen all report insufficient balance‑sheet or growth data, resulting in neutral scores around 50. Risk‑focused frameworks such as Loeb, Howard Marks, Jesse Livermore and Samuel Nelson interpret the same data as moderate risk, mixed expectations, or a mid‑cycle signal, with scores in the high‑40s. The more volatility‑averse viewpoints of Morgan Housel and Jack Schwager, however, estimate that the stock's price swings and lack of a clear setup merit staying out, reflected in their lower scores of 38 and 36.
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 64
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 57
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 55
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 47
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 45
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 40
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 38
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 36
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 33
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 20
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 5
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 1 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 27.8.2026 | $0.170 |
| 23.3.2026 | $0.250 |
| 22.3.2026 | $0.250 |
| 17.3.2025 | $0.200 |
| 16.3.2025 | $0.200 |
Sentiment based on basic keywords (not AI) — 9 positive, 9 neutral, 2 negative out of the last 20 articles.
MT Newswires · 17.9.2026
GlobeNewswire · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 10.9.2026
GlobeNewswire · 10.9.2026
Benzinga · 8.9.2026
Yahoo · 3.9.2026
GlobeNewswire · 3.9.2026
SeekingAlpha · 1.9.2026
Motley Fool · 19.8.2026
GlobeNewswire · 17.8.2026
Zacks · 14.8.2026
Zacks · 14.8.2026
Zacks · 14.8.2026
Zacks · 13.8.2026
GuruFocus.com · 12.8.2026
Moby · 12.8.2026
MarketBeat · 12.8.2026
Zacks · 12.8.2026
Zacks · 12.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Kamada Ltd. (KMDA) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for KMDA specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
KMDA's technical score is 89/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 50-day average; Price is above the 200-day average; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: %K 96.9 — overbought.
Yes — KMDA has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 5,000 | -5,000 | — |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 5,000 | -5,000 | — |
| Tsur David | Open Market Sale | 14.9.2026 | 22,827 | -22,827 | $8.18 |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 5,464 | -5,464 | — |
| Livneh Nir | Tax Withholding in Shares | 14.9.2026 | 3,459 | -3,459 | $8.35 |
| Livneh Nir | Exercise of Derivative Securities | 14.9.2026 | 10,000 | +10,000 | $5.37 |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 5,000 | -5,000 | — |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 5,000 | +5,000 | $5.93 |
| Brenner Yael | Tax Withholding in Shares | 14.9.2026 | 1,371 | -1,371 | $8.36 |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 6,500 | -6,500 | — |
| Livneh Nir | Exercise of Derivative Securities | 14.9.2026 | 10,000 | -10,000 | — |
| Brenner Yael | Tax Withholding in Shares | 14.9.2026 | 1,371 | -1,371 | $8.36 |
| Brenner Yael | Tax Withholding in Shares | 14.9.2026 | 1,783 | -1,783 | $8.36 |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 5,000 | +5,000 | $5.93 |
| Brenner Yael | Tax Withholding in Shares | 14.9.2026 | 1,499 | -1,499 | $8.35 |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 5,000 | +5,000 | $5.93 |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 5,464 | +5,464 | $5.93 |
| Brenner Yael | Tax Withholding in Shares | 14.9.2026 | 1,371 | -1,371 | $8.36 |
| Brenner Yael | Exercise of Derivative Securities | 14.9.2026 | 6,500 | +6,500 | $5.93 |
| Tsur David | Open Market Sale | 9.9.2026 | 175 | -175 | $8.26 |
| Tsur David | Open Market Sale | 8.9.2026 | 162,760 | -162,760 | $8.26 |
| Tsur David | Open Market Sale | 7.9.2026 | 14,238 | -14,238 | $8.28 |
| Tsur David | Tax Withholding in Shares | 2.9.2026 | 2,760 | -2,760 | $8.30 |
| Tsur David | Exercise of Derivative Securities | 2.9.2026 | 22,500 | +22,500 | $5.94 |
| Tsur David | Tax Withholding in Shares | 2.9.2026 | 6,406 | -6,406 | $8.26 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
156,782 shares short as of 2026-08-31 · vs. 131,138 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.1% of trading volume this week was short selling, vs. 44.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology